Evidence suggests that Elavl1 acts as an oncogene, enhancing the transcriptional activity of target mRNAs and promoting cancer hallmarks, such as sustained proliferative signalling, evasion of growth suppression, invasion and metastasis, induction of angiogenesis, replicative immortality, inhibition of cell death, and promotion of tumour-related inflammation and immune evasion [86–93]. Here, ELAVL1 is linked to cancer.